National and Kapodistrian University of Athens
Μεταμόσχευση νεφρού υπερευαισθητοποιημένων ασθενών με το πρόγραμμα των αποδεκτών ασύμβατων αντιγόνων
Abstract
dc:descriptionHighly sensitized patients (HSP) have a low chance to find a compatible kidney allograft. According to the kidney allocation program in Greece, HSP with panel reactive antibody -%PRA>70 enter a priority list and proceed to crossmatch if the donor does not express unacceptable HLA-A,-B,-C,-DR,-DQ molecules. Patients with negative CDC and T/B Flow cytometric crossmatch (T/B FCXM) with the donor receive the graft. This study discusses the long term outcome of 97 highly sensitized renal transplant recipients. Our high immunologic risk program included 97 HSP who received a graft between January 2004 and December 2016 in Laikon Hospital, Athens. Their characteristics were compared with a control group (CG) including 96 non sensitized patients, transplanted in the same period. The HSP were divided into 2 groups: group A- 35 patients (36.08%) transplanted with preformed donor specific antibodies (DSAs), (HSP/DSA+), with median MFI=3332 (IQR: 1656-4842) on day 0 and group B- 62 patients (63.9%) without DSAs (MFI<1000), (HSP/DSA-). All patients were transplanted with negative CDC and T/B FCXM and received induction therapy with Basiliximab. Additionally, Rituximab was given in 18 pts of HSP/DSA+ group. Eleven patients of HSP/DSA+ group also received 3 plasma exchanges with low dose IVIG.Τhe seven–year patient survival was 95.3% (SE=2.3%) in the HSP and 91.7% (SE=3.0) in the CG ( p=0.274). The seven-year graft survival was 90.1% (SE=3.2%) in the HSP and 95.3% (SE=2.3%) in the CG (p=0.253). The HSP experienced an increased risk of biopsy proven acute rejection episodes, as compared to CG. However, the difference did not reach statistical significance (p=0.523). There was a significant difference in the number of patients who experienced acute rejection episodes, especially cellular rejections, in the HSP/DSA+ group compared to those in HSP/DSA- group (p=0.025). Patient survival rates were similar in the two groups (p=0.496). No difference was observed in graft survival rates (p=0.924). No statistical difference was observed regarding infections, surgical complications and malignancies among all study groups.We conclude that renal transplantation in HSP with unacceptable mismatch antigen program and negative CDC and T/B FCXM is safe, with low immunological risk.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2021
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Darema, Maria
- Δαρεμά, Μαρία
Subjects
dc:subject × 8Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/48863